

Clinical research

Characteristics and clinical outcomes of patients with sarcoidosis admitted for ST-elevation myocardial infarction in the United States: a propensity matched analysis from the National Inpatient Sample

Raheel Ahmed^{1,2}, Noem Najam³, Kamleshun Ramphul⁴, Sebastian Mactaggart⁵, Mansimran Sigh Dulay¹, Joseph Okafor¹, Alessia Azzu¹, Maham Bilal³, Rahat A Memon⁶, Hemamalini Sakthivel⁷, Rajdeep Khattar¹, Athol Umfrey Wells¹, John Arun Baksi¹, Kshama Wechalekar¹, Vasilis Kouranos¹, Anwar Chahal^{8,9,10}, Rakesh Sharma^{1,2}

¹Cardiac Sarcoidosis Services, Royal Brompton Hospital, London, United Kingdom

²National Heart and Lung Institute, Imperial College London, United Kingdom

³Dow University of Health Sciences, Karachi, Pakistan

⁴Independent Researcher, Triolet, Mauritius

⁵Northumbria Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

⁶Abington Hosp- Jefferson Health, Horsham, United States

⁷One Brooklyn Health System/Interfaith Medical Ctr Program, Brooklyn, New York, United States

⁸Department of Cardiology, Barts Heart Centre, London, United Kingdom

⁹Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

¹⁰Center for Inherited Cardiovascular Diseases, Department of Cardiology, Wellspan Health, York, USA

Corresponding author:

Sebastian Mactaggart
Northumbria Hospitals
NHS Foundation Trust
Newcastle upon Tyne
United Kingdom
E-mail: seb.mactaggart@hotmail.com

Submitted: 23 January 2024; **Accepted:** 20 February 2024

Online publication: 8 March 2024

Arch Med Sci Atheroscler Dis 2024; 9: e47–e55

DOI: <https://doi.org/10.5114/amsad/184701>

Copyright © 2024 Termedia & Banach

Abstract

Introduction: Sarcoidosis is a systemic inflammatory disorder characterised by non-caseating granulomas. Cardiac sarcoidosis (CS) normally causes conduction abnormalities, ventricular arrhythmias, and heart failure. Little is known about the characteristics and impact of sarcoidosis in patients admitted with ST-elevation myocardial infarction (STEMI). This study aims to fill this void.

Material and methods: Utilising the National Inpatient Sample (NIS) database (2016–2020), individuals with STEMI were identified and categorised based on sarcoidosis presence whilst adjusting for confounders via logistic regression models.

Results: Among 851,290 STEMI patients, 1215 had sarcoidosis. Before propensity matching, sarcoidosis patients were notably different in demographics and comorbidities compared to non-sarcoidosis patients. After propensity score matching (PSM), sarcoidosis patients were found to have a higher incidence of supraventricular tachycardia (SVT) (2.5% vs. 1.3%, $p = 0.024$) and acute kidney injury (AKI) (23.3% vs. 20.8%, aOR = 1.269, 95% CI: 1.02–1.58, $p = 0.033$) but a lower incidence of undergoing coronary artery bypass graft (CABG) (5.5% vs. 8.5%, aOR = 0.663; 95% CI: 0.472–0.931, $p = 0.018$), while no significant disparities were noted in PCI, cardiogenic shock, mortality, or mean length of stay (LOS).

Conclusions: Using propensity-matched large real-world data of STEMI patients, sarcoidosis was associated with fewer cases of CABG and a greater incidence of AKI and SVT compared to non-sarcoidosis patients.

Key words: ST-elevation myocardial infarction, sarcoidosis, cardiac sarcoidosis, propensity matched.

Introduction

Sarcoidosis is a systemic inflammatory disorder characterised by the development of non-caseating granulomas, which are aggregates of immune cells, in various organs throughout the body [1]. Whilst the aetiology is not fully understood, there is a suggestion that environmental stimuli trigger an aberrant immune reaction in genetically susceptible individuals, resulting in granuloma formation [2]. Although sarcoidosis primarily manifests in the pulmonary system, often characterised by symptoms of a persistent dry cough, fatigue, and dyspnoea, its presentation is not limited to the lungs. Other organs, such as the heart, can also be involved [1]. Although myocardial involvement presents symptomatically in approximately 10% of individuals, the associated risk of morbidity and mortality render cardiac sarcoidosis (CS) as a key manifestation of the disease [3, 4]. When there is involvement of the myocardium, the regular electrical conduction may be disrupted and there may be hinderance of the normal cardiac ability to pump effectively. This can result in a range of manifestations including atrioventricular (AV) block, ventricular tachyarrhythmias, and heart failure [4, 5].

ST-elevation myocardial infarction (STEMI) is commonly attributed to atherosclerotic plaque rupture with subsequent occlusion of the coronary artery. Although there are conflicting results between studies, there is research that provides empirical evidence linking a greater risk of STEMI and a diagnosis of sarcoidosis [6–8]. It has been hypothesised that the elevated risk of STEMI in this cohort can be attributed to the alterations in lipid metabolism seen in sarcoidosis, as well as the inflammatory nature of the disease, which both lead to an increased the risk of atherosclerosis [9, 10]. However, to our knowledge there are currently no data available on how the presentation, impact, and outcome of STEMI differs in patients with sarcoidosis versus the general population.

This study aims to address this absence in the literature using propensity-matched real-world data.

Material and methods

Study population

This retrospective study encompassed individuals aged 18 years or older admitted between 2016 and 2020 from the STEMI identified through the International Classification of Diseases, 10th Revision (ICD-10) codes, based on recommendations from previous studies. They were then stratified into groups of individuals with sarcoidosis and without sarcoidosis. The de-identified nature of the NIS waives the need for Ethics and Institution-

al Review Board approvals. All ICD-10 codes used for our study are available in Supplementary 1 [11–17].

Statistical analysis

Initially, χ^2 tests were employed to assess the association between the presence of sarcoidosis in STEMI patients and various categorical variables. These included sex, insurance status, race, smoking status, presence of diabetes, hypertension, cirrhosis, alcohol abuse, drug abuse, peripheral vascular disease (PVD), obesity, chronic kidney disease (CKD), lipid disorder, history of myocardial infarction (MI) or stroke, hospital type, and age group (≥ 60 years vs. < 60 years). This was followed by an evaluation of cardiac arrhythmia events. The main aim of this study is to assess and compare the intersectionality and comorbid status of patients with STEMI who have sarcoidosis and those who do not have sarcoidosis. The second objective of this study is to evaluate a range of outcomes, such as the duration of hospitalisation, acute ischaemic stroke (AIS), coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), acute kidney injury (AKI), cardiogenic shock, and mortality, among these specific patient cohorts.

Subsequently, propensity score matching was conducted via R-Studio, adjusting for the aforementioned variables along with age. A 1 : 1 ratio matching with a calliper of 0.2 was utilised to create balanced groups between sarcoidosis and non-sarcoidosis cohorts. A multivariate regression analysis was performed to discern differences in outcomes between the sarcoidosis and non-sarcoidosis groups.

Analytical software

Statistical analyses were carried out using SPSS version 29.0 and R-Studio, leveraging their respective functionalities for data curation, propensity score matching, and regression analyses.

Results

There were 851,290 patients with STEMI recruited in this study, of whom 1215 had sarcoidosis (Table I). Both groups involved mostly males (58.4% vs. 69.5%, $p < 0.01$) and patients aged ≥ 60 years (64.6% vs. 60.9%, $p < 0.01$). Patients with sarcoidosis expressed a higher prevalence among females than those without sarcoidosis (41.6% vs. 30.5%, $p < 0.01$). The prevalence of White and Hispanic individuals within the sarcoidosis cohort was lower (65.3% vs. 75.5% and 3.8% vs. 8.6%, respectively, both $p < 0.01$), with Black individuals making up a higher proportion (27.1% vs. 8.8%, $p < 0.01$). Although a marginal

Table I. Characteristics and outcomes of patients with and without sarcoidosis admitted for ST-elevation myocardial infarction (STEMI) in the United States between 2016–2020

Characteristics	Non-sarcoidosis (n = 850,075) (%)	Sarcoidosis (n = 1215) (%)	P-value
Comorbidities and patient and hospital characteristics:			
Female	30.5	41.6	< 0.01
Age 60 or more years	60.9	64.6	< 0.01
Mean age	63.56	63.77	< 0.01
Race:			< 0.01
White	75.5	65.3	
Black	8.8	27.1	
Hispanic	8.6	3.8	
Hospital type:			0.030
Rural	6.5	6.6	
Urban non-teaching	21.6	18.5	
Urban teaching	71.9	74.9	
Insurance form:			< 0.01
Medicare	44.9	54.7	
Medicaid	10.6	6.6	
Private	33.8	35.4	
Mean CCI score	2.68	3.14	0.652
Smoking	52.0	35.4	< 0.01
Lipid disorder	64.6	71.2	< 0.01
Diabetes	32.4	42.4	< 0.01
Hypertension	47.7	45.3	0.090
Cirrhosis	0.5	1.6	< 0.01
Drug abuse	2.8	1.2	< 0.01
Alcohol abuse	3.5	2.1	< 0.01
Depression	6.7	9.1	< 0.01
Peripheral vascular disease	5.1	7.8	< 0.01
Obesity	17.8	24.3	< 0.01
Chronic kidney disease	13.1	25.9	< 0.01
Old MI	11.9	11.9	0.976
Prior stroke	5.2	7.4	< 0.01
Events of cardiac arrhythmias:			
Atrial fibrillation	14.0	15.6	0.106
SVT	2.2	2.5	0.463
Ventricular tachycardia	12.6	11.9	0.456
Ventricular fibrillation	11.1	11.1	0.969
Atrial flutter	1.7	1.2	0.231
Procedures and other outcomes:			
CABG	5.3	5.8	0.443
PCI	79.8	75.3	< 0.01
AIS	1.4	1.2	0.600
Cardiogenic shock	13.7	12.3	0.158
AKI	17.1	23.5	< 0.01
Died	7.9	8.6	0.386
Mean LOS [days]	4.01	4.76	< 0.01

AIS – acute ischaemic stroke, CABG – coronary artery bypass grafting, CCI – Charlson Comorbidity Index, LOS – length of stay, MI – myocardial infarction, PCI – percutaneous coronary intervention, SVT – supraventricular tachycardia.

Table II. Characteristics and outcomes of patients with and without sarcoidosis admitted for STEMI in the United States between 2016 and 2020 after propensity score matching

Characteristics	Non-sarcoidosis (n = 1180) (%)	Sarcoidosis (n = 1180) (%)	P-value
Comorbidities and patient and hospital characteristics:			
Female	40.7	41.1	0.834
Age 60 and more years	67.4	65.3	0.276
Race:			0.061
White	68.2	65.3	
Black	23.3	27.1	
Hispanic	4.2	3.8	
Insurance form:			0.111
Medicare	54.2	54.7	
Medicaid	8.5	6.8	
Private	35.2	35.2	
Smoking	35.2	35.6	0.830
Diabetes	45.8	42.8	0.147
Hypertension	46.2	45.8	0.836
Cirrhosis	2.1	1.7	0.452
Drug abuse	*	*	0.025
Alcohol abuse	1.7	2.1	0.452
Lipid disorder	69.1	71.6	0.176
Peripheral vascular disease	7.6	7.6	1
Obesity	22.9	24.2	0.467
Chronic kidney disease	24.6	25.4	0.635
Old MI	9.7	11.9	0.097
Prior stroke	7.2	7.2	1
Hospital type:			0.230
Rural	7.6	6.4	
Urban non-teaching	20.3	18.6	
Urban teaching	72.0	75.0	
Events of cardiac arrhythmias:			
Atrial fibrillation	14.4	15.7	0.388
SVT	1.3	2.5	0.024
Ventricular tachycardia	11.4	11.9	0.748
Ventricular fibrillation	11.4	11.4	1
Atrial flutter	1.3	1.3	1
Procedures and other outcomes:			
CABG	8.5	5.5	0.014
PCI	78.4	75.4	0.087
AIS	*	*	0.315
Cardiogenic shock	13.6	11.9	0.216
AKI	20.8	23.3	0.136
Died	9.3	8.5	0.470
Mean age	65.29	63.82	< 0.01
Mean LOS	4.59	4.76	0.052
Mean CCI score	3.14	3.15	0.170

AIS – acute ischaemic stroke, CABG – coronary artery bypass grafting, CCI – Charlson Comorbidity Index, LOS – length of stay, MI – myocardial infarction, PCI – percutaneous coronary intervention, STEMI – ST-elevation myocardial infarction, SVT – supraventricular tachycardia.

Table III. Adjusted odds ratio of events in patients with and without sarcoidosis (reference) admitted for STEMI in the United States

Parameter	P-value	aOR	Lower 95% CI	Upper 95% CI
CABG	0.018	0.663	0.472	0.931
PCI	0.174	0.866	0.705	1.065
Cardiogenic shock	0.392	0.896	0.696	1.153
AKI	0.033	1.269	1.020	1.578
Died	0.899	0.980	0.720	1.335

AKI – acute kidney injury, aOR – adjusted odds ratio, CABG – coronary artery bypass grafting, CI – confidence interval, PCI – percutaneous coronary intervention, STEMI – ST-elevation myocardial infarction.

difference, sarcoidosis patients were more likely to be admitted to urban teaching hospitals (74.9% vs. 71.9%, $p = 0.030$).

Regarding comorbidities, there was significant variation seen between the 2 groups. Those within the sarcoidosis cohort demonstrated lower rates of smoking (35.4% vs. 52.0%, $p < 0.01$) and higher occurrences of diabetes (42.4% vs. 32.4%, $p < 0.01$), cirrhosis (1.6% vs. 0.5%, $p < 0.01$), depression (9.1% vs. 6.7%, $p < 0.01$), peripheral vascular disease (7.8% vs. 5.1%, $p < 0.01$), obesity (24.3% vs. 17.8%, $p < 0.01$), chronic kidney disease (25.9% vs. 13.1%, $p < 0.01$), lipid disorder (71.2% vs. 64.6%, $p < 0.01$), and prior stroke (7.4% vs. 5.2%, $p < 0.01$). However, there were no statistically significant differences observed between the groups for hypertension (45.3% vs. 47.7%, $p = 0.090$), alcohol abuse (2.1% vs. 3.5%, $p = 0.091$), old myocardial infarction (11.9% vs. 11.9%, $p = 0.976$), or mean Charlson Comorbidity Index (CCI) score (3.14 vs. 2.68, $p = 0.652$). There were no significant differences in the occurrence of several cardiac arrhythmias, such as atrial fibrillation (15.6% vs. 14.0%, $p = 0.106$), supraventricular tachycardia (SVT) (2.5% vs. 2.2%, $p = 0.463$), ventricular tachycardia (11.9% vs. 12.6%, $p = 0.456$), ventricular fibrillation (11.1% vs. 11.1%, $p = 0.969$), or atrial flutter (1.2% vs. 1.7%, $p = 0.231$).

Rates of PCI in the sarcoidosis cohort were lower than those for non-sarcoidosis patients (75.3% vs. 79.8%, $p < 0.01$), and the patients were more likely to have an increased mean length of stay (LOS) (4.76 vs. 4.01 days, $p < 0.01$). Sarcoidosis patients had a significantly higher incidence of acute kidney injury (AKI) (23.5% vs. 17.1%; $p < 0.01$); however, there were no significant differences between the sarcoidosis and non-sarcoidosis groups in rates of coronary artery bypass graft (CABG), acute ischaemic stroke (AIS), cardiogenic shock, or mortality.

After propensity score matching (PSM), 1180 patients were assessed in each cohort, maintaining balance in characteristics and co-morbid conditions (Table II). Accordingly, comparable distributions were observed in demographic attributes, comorbidities, and hospital character-




Figure 1. Adjusted odds ratio of events in patients with and without sarcoidosis (reference) admitted for STEMI in the United States

istics between sarcoidosis and non-sarcoidosis patients. The results demonstrate that the only notable difference relating to outcome was having lower rates of CABG seen in the sarcoidosis cohort (5.5% vs. 8.5%, $p = 0.014$). Previously observed differences in the incidence of AKI, PCI, and mean LOS were no longer evident after PSM. Concerning the aforementioned cardiac arrhythmias, SVT was observed significantly more in the sarcoidosis group (2.5% vs. 1.3%, $p = 0.024$), whilst the other arrhythmias were seen in similar distributions between the 2 cohorts.

In the adjusted outcomes analysis (Table III, Figure 1), sarcoidosis was associated with a lower incidence of CABG (adjusted odds ratio [aOR] = 0.663; 95% confidence interval [CI]: 0.472–0.931, $p = 0.018$), and high rates of AKI (aOR = 1.269, 95% CI: 1.02–1.58, $p = 0.033$). Conversely, the presence of sarcoidosis had no significant effect on the incidence of PCI, cardiogenic shock, mortality, and LOS.

Discussion

The primary findings from our analyses of this large, nationwide data set were threefold. Firstly, other than the lower rates of smoking seen in the sarcoidosis cohort, STEMI patients with co-existing sarcoidosis generally presented with a greater burden of co-morbidities when compared to the non-sarcoidosis group. Secondly, sarcoidosis was associated with an increased incidence of SVT and

AKI. Finally, those within the sarcoidosis group had a lower incidence of CABG post-STEMI.

Patient characteristics

This study demonstrated significant disparities in patient characteristics between the 2 groups. Overall, there were more male patients with STEMI in both of our cohorts, which can be attributed to the well-documented difference in the prevalence of myocardial infarction between sexes [18]. However, when looking at each subgroup, there was a higher proportion of females seen in the sarcoidosis group compared to the non-sarcoidosis group. This finding is in keeping with previous research which shows a greater incidence of sarcoidosis in females [19].

Our research findings also showed significant racial disparities between the 2 groups, in particular relating to the greater proportion of Black individuals seen within the sarcoidosis cohort. Again, this finding is consistent with existing data, such as the review of 9 studies from Hena which showed a tendency for sarcoidosis to affect Black individuals [20]. More specifically, this review showed that Black females were at greatest risk of morbidity and mortality associated with sarcoidosis – a finding also replicated from studies not just in the United States, but across the world [19].

The analysis also investigated insurance patterns amongst those with sarcoidosis. Medicaid is a joint federal and state initiative that provides healthcare insurance coverage to households with low incomes [21]. In our study, those with Medicaid showed lower prevalence of STEMI, with the converse being true of those with private insurance. This may indicate a correlation between STEMI occurrence in sarcoidosis patients and a higher socio-economic status. Although there is limited evidence to support or refute this finding, reports suggest that in those with sarcoidosis it is in fact lower socioeconomic status that is associated with worsened morbidity and mortality [22].

Co-morbidities

We demonstrated that individuals diagnosed with sarcoidosis were less likely to be smokers but had higher prevalence rates of diabetes, cirrhosis, depression, peripheral vascular disease, obesity, and chronic kidney disease.

Several previous studies suggest that smoking may be a protective factor against developing pulmonary sarcoidosis but may elevate the risk of extrapulmonary manifestations [23, 24]. However, as is true of many presentations of sarcoidosis, geoepidemiological variations between populations are associated with diverse and var-

ied manifestations. For instance, although a Japanese study showed higher rates of pulmonary sarcoidosis with a lower incidence of cutaneous involvement in current smokers [25], a study from India showed no significant link between smoking and sarcoidosis [26]. Blanchet *et al.* investigated the impact of nicotine therapy on hypersensitivity pneumonitis, a different disease also characterised by granulomatous formation. Although this study investigated hypersensitivity pneumonitis, the outcomes from this research potentially have broader implications for other granulomatous diseases such as sarcoidosis. This study showed nicotine therapy to reduce white blood cell counts across all cell types, sparing CD8 lymphocytes, but more relevantly to our study – CD4 lymphocytes as well [27]. Although CD4+ lymphocytes play a central role in the development of granuloma formation, and consequently sarcoidosis, if these are unaffected by nicotine as extrapolated from this study, then this would imply that other white blood cells may be involved in the pathogenesis of the disease. This would result in a reduced incidence of sarcoidosis in those who smoke, a finding in keeping with the results seen in our study [2]. However, this postulation and result is hypothesis generating at best.

Our study showed those with sarcoidosis had high incidences of metabolic syndromes such as diabetes and obesity. Previous studies, such as a systematic review from 2021, also showed statistical significance linking sarcoidosis and diabetes [28]. Other prior studies from Cozier *et al.* (2014) and Ungprasert *et al.* (2016) correlated sarcoidosis with obesity, with the authors postulating that this relationship could be explained by the presence of increased levels of leptin, an immunomodulatory hormone that is more readily secreted in obese individuals [29, 30]. In turn, leptin induces immune cell proliferation, in particular upon the naive T-cells, which triggers a shift towards Th1 immunity – a process that may be implicated in the development of sarcoidosis [31].

The elevated depression rates seen in our study also align with previous investigations by Hinz *et al.* (2012), Goracci *et al.* (2008), and Chang *et al.* (2001) [32–34]. However, due to the absence of sufficient data pertaining to the temporal relationship between the development of this condition and the manifestation of sarcoidosis, there is ambiguity regarding the causality of this association.

One such explanation for this relationship may lie in the treatment of sarcoidosis using immunosuppression. Side effect profiles of these medications leading to symptoms such as neuropsychological disturbances may account for the higher rates of depression seen in this cohort, with other

Cushing's syndrome features such as central adiposity and insulin resistance leading to obesity and diabetes [1, 35]. Further research is warranted to elicit whether these associations between sarcoidosis, metabolic syndromes, and depression are in fact causal or are of a consequence of glucocorticoid therapy.

The current study also demonstrated higher prevalence of liver cirrhosis among individuals with sarcoidosis, which is consistent with findings from small-scale studies and case reports [36–41]. Cirrhosis in sarcoidosis patients has been hypothesised to be a direct consequence of granuloma formation in the liver [41]. Similarly PVD, another comorbidity variable which reached significance in the sarcoidosis cohort, has been plausibly linked to vasculitic lesions in the peripheral vessels due to granulomatous inflammation [42]. Although existing literature indicates a propensity for sarcoidosis to impact renal function in the context of acute renal injury, our study also found that CKD emerged as a comorbidity seen more frequently in the sarcoidosis cohort [43–45]. The association between sarcoidosis and chronic renal disease, liver cirrhosis, and PVD are scarcely discussed in the literature, and although we have established a significant correlation, further research is necessary to establish an accurate narrative.

Cardiac events and arrhythmias

We expected that, as a consequence of the highly arrhythmogenic nature of cardiac sarcoidosis (CS), there would be a link between sarcoidosis patients in this cohort and arrhythmia. After propensity matching, our analysis showed significance linking supraventricular tachycardia (SVT) and sarcoidosis, in keeping with our hypothesis. Desai *et al.* (2016) observed arrhythmias, primarily atrial fibrillation, in around 20% of sarcoidosis patients [46], with a subsequent study from Yasuda *et al.* (2016) identifying ventricular tachyarrhythmias as the predominant cardiac event observed in individuals diagnosed with cardiac sarcoidosis [47]. A more recent meta-analysis from Mahmoud *et al.* (2020) highlighted unspecified arrhythmias as the third most prevalent cardiac comorbidity in sarcoidosis cases [48].

Notably, without propensity matching, we found no correlation between cardiac arrhythmias and sarcoidosis. We suspect this may be due to confounding factors, primarily age. A study conducted by Piccini *et al.* showed escalating incidences of atrial fibrillation with respect to increasing age, specifically among individuals aged 65 years and above [49]. On a similar note, the previously discussed study by Desai *et al.* (2016) observed a statistically significant difference in age between the sarcoidosis cohort with arrhythmias (mean age

61.9 years) and the sarcoidosis cohort without arrhythmias (mean age 56.0 years) [46]. As such, it can be stated that the incidence of arrhythmias increases with age regardless of the presence of sarcoidosis. The mean ages for both groups in our study are relatively similar, and therefore the absence of significant variation between groups may not reflect reduced arrhythmia rates in the sarcoidosis group, but rather increased rates of arrhythmia in the non-sarcoidosis group due to the elderly nature of the population observed in our study.

Outcomes

PCI is widely regarded as the preferred therapeutic approach for most cases involving STEMI [50]. CABG is a major surgical operation reserved for cases not amenable to PCI [51]. While our study indicates decreased rates of CABG and PCI in sarcoidosis, there are few data specifically addressing STEMI treatment in sarcoidosis, so these findings could not be corroborated [52]. Further research observing the type of coronary artery vessels, the number of arteries, and the type of lesions involved are needed to draw meaningful conclusions.

Notably, sarcoidosis patients had higher AKI rates, aligning with prior studies outlining the occurrence of AKI in sarcoidosis [45, 53–55]. STEMI leads to a reduction in cardiac output, resulting in a pre-renal injury to the kidneys [56]. In the sarcoidosis group, AKI may have occurred more frequently due to the compounding effects of STEMI superimposed onto the granulomatous interstitial nephritis and hypercalcaemia thought to cause AKI in sarcoidosis patients [55, 57, 58].

Strengths and limitations

This study's primary strength lies in its extensive sample size, offering diverse representations reflective of the target population. Furthermore, the study is robust due to minimising selection bias. However, its retrospective nature limits the comprehensiveness of the data. It prevents us from truly establishing clear temporal relationships between variables and challenging accurate causality inferences. Moreover, adjustments were limited to collected variables, potentially missing other confounding factors specific to this study. Lastly, the data's exclusive focus on the United States warrants caution in generalising findings to other populations, because well-documented demographic variations between those with sarcoidosis may not be captured by our results.

In conclusion, STEMI patients with sarcoidosis carry a higher burden of comorbidities compared to those without sarcoidosis. Additionally, although we identified STEMI patients with co-ex-

isting sarcoidosis to exhibit worsened outcomes, it is important to note that these outcomes are probably influenced by confounding variables associated with sarcoidosis rather than being a direct consequence of the condition itself. Using a large, propensity matched, real-world dataset of STEMI patients, we showed sarcoidosis to be associated with fewer cases of CABG and a greater incidence of AKI and SVT when compared to non-sarcoidosis patients.

Acknowledgments

Raheel Ahmed and Noem Najam contributed equally. Anwar Chahal and Rakesh Sharma contributed equally.

Funding

No external funding.

Ethics approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1. Bokhari SRA, Zulfiqar H, Mansur A. Sarcoidosis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430687/>
2. Moller DR, Rybicki BA, Hamzeh NY, et al. Genetic, immunologic, and environmental basis of sarcoidosis. *Ann Am Thorac Soc* 2017; 14 (Suppl 6): S429-36.
3. Mahmoud AR, Dahy A, Dibas M, Abbas AS, Ghozy S, El-Qushayri AE. Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis. *Heart Lung* 2020; 49: 512-7.
4. Hussain K, Shetty M. Cardiac sarcoidosis. [Updated 2023 Jan 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK578192/>
5. Polverino F, Balestro E, Spagnolo P. Clinical presentations, pathogenesis, and therapy of sarcoidosis: state of the art. *J Clin Med* 2020; 9: 2363.
6. Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013. *Eur Respir J* 2017; 49: 1601290.
7. Rossides M, Kullberg S, Grunewald J, et al. Risk of acute myocardial infarction in sarcoidosis: a population-based cohort study from Sweden. *Respir Med* 2021; 188: 106624.
8. Aikawa T, Koyanagawa K, Oyama-Manabe N, Anzai T. Cardiac sarcoidosis mimicking myocardial infarction: a comprehensive evaluation using computed tomography and positron emission tomography. *J Nucl Cardiol* 2020; 27: 1066-7.
9. Bargagli E, Rosi E, Pistolesi M, Lavorini F, Voltolini L, Rotoli P. Increased risk of atherosclerosis in patients with sarcoidosis. *Pathobiology* 2017; 84: 258-63.
10. Hoss S, Grinberg T, Eisen A. The interrelationship between sarcoidosis and atherosclerosis-complex yet rational. *J Clin Med* 2022; 11: 433.
11. Taneja V, Stein DJ, Feuerstein JD. Impact of cirrhosis on outcomes in inflammatory bowel disease hospitalizations. *J Clin Gastroenterol* 2022; 56: 718-23.
12. Elixhauser Comorbidity Software Refined For ICD-10-CM [Available from: https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp].
13. Ramphul K, Sombans S, Verma R, et al. Characteristics and outcomes of 7620 multiple sclerosis patients admitted with COVID-19 in the United States. *medRxiv* 2023; 2023.02.15.23285994.
14. Sawatari H, Chahal AA, Ahmed R, et al. Impact of cardiac implantable electronic devices on cost and length of stay in patients with surgical aortic valve replacement and transcatheter aortic valve implantation. *Am J Cardiol* 2023; 192: 69-78.
15. Elbadawi A, Elgendy IY, Omer M, et al. Outcomes of acute myocardial infarction in patients with familial hypercholesterolemia. *Am J Med* 2021; 134: 992-1001.e4.
16. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2016, 2017, 2018, 2019, 2020. Agency for Healthcare Research and Quality, Rockville, MD. 2022 [Available from: <https://www.hcup-us.ahrq.gov/nisoverview.jsp>].
17. Manansala M, Sami F, Arora S, Manadan AM. Reasons for hospitalization and all-cause mortality for adults with sarcoidosis. *Am J Med Open* 2023; 9: 100037.
18. Schulte KJ, Mayrovitz HN. Myocardial infarction signs and symptoms: females vs. males. *Cureus* 2023; 15: e37522.
19. Brito-Zerón P, Kostov B, Superville D, Baughman RP, Ramos-Casals M; Autoimmune Big Data Study Group. Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. *Clin Exp Rheumatol* 2019; 37: 1052-64.
20. Hena KM. Sarcoidosis epidemiology: race matters. *Front Immunol* 2020; 11: 537382.
21. Hill SC, Abdus S. The effects of Medicaid on access to care and adherence to recommended preventive services. *Health Serv Res* 2021; 56: 84-94.
22. Sharp M, Eakin M, Drent Marjolein. Socioeconomic determinants and disparities in sarcoidosis. *Curr Opin Pulmonary Med* 2020; 26: 568-73.
23. Janot AC, Huscher D, Walker M, et al. Cigarette smoking and male sex are independent and age concomitant risk factors for the development of ocular sarcoidosis in a New Orleans sarcoidosis population. *Sarcoidosis Vasc Diffuse Lung Dis* 2015; 32: 138-43.
24. Krell W, Bourbonnais JM, Kapoor R, et al. Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis. *Lung* 2012; 190: 529-36.
25. Hattori T, Konno S, Shijubo N, Ohmichi M, Nishimura M. Prevalence of smoking in sarcoidosis. *Respirology* 2013; 18: 1152-7.
26. Gupta D, Singh AD, Agarwal R, Aggarwal AN, Joshi K, Jindal SK. Is tobacco smoking protective for sarcoidosis? A case-control study from North India. *Sarcoidosis Vasc Diffuse Lung Dis* 2010; 27: 19-26.
27. Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. *Am J Respir Crit Care Med* 2004; 169: 903-9.
28. Benmelouka AY, Abdelaal A, Mohamed ASE, et al. Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis. *Exp Rev Respir Med* 2021; 12: 1589-95.

29. Cozier YC, Coogan PF, Govender P, Berman JS, Palmer JR, Rosenberg L. Obesity and weight gain in relation to incidence of sarcoidosis in US black women: data from the Black Women's Health Study. *Chest* 2015; 147: 1086-93.
30. Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: a population-based nested case-control study. *Respir Med* 2016; 120: 87-90.
31. Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. *Mol Aspects Med* 2012; 33: 35-45.
32. Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. *Sarcoidosis Vasc Diffuse Lung Dis* 2012; 29: 139-46.
33. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. *Gen Hosp Psychiatry* 2008; 30: 441-5.
34. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. *Am J Respir Crit Care Med* 2001; 163: 329-34.
35. Bauerle KT, Harris C. Glucocorticoids and Diabetes. *Mo Med* 2016; 113: 378-83.
36. Kennedy PT, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. *Eur J Gastroenterol Hepatol* 2006; 18: 721-6.
37. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. *Am J Surg Pathol* 1993; 17: 1272-80.
38. Gupta S, Faughnan ME, Prud'homme GJ, Hwang DM, Munoz DG, Kopplin P. Sarcoidosis complicated by cirrhosis and hepatopulmonary syndrome. *Can Respir J* 2008; 15: 124-6.
39. Malhotra A, Naniwadekar A, Sood G. Hepatobiliary and pancreatic: cirrhosis secondary to hepatic sarcoidosis. *J Gastroenterol Hepatol* 2008; 23: 1942.
40. Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. *Am J Med* 1975; 59: 373-87.
41. Tadros M, Forouhar F, Wu GY. Hepatic sarcoidosis. *J Clin Transl Hepatol* 2013; 1: 87-93.
42. Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angitis in sarcoidosis. *Arch Pathol Lab Med* 1977; 101: 170-4.
43. Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2003; 20: 126-32.
44. Ueda S, Murakami T, Ogino H, et al. Systemic sarcoidosis presenting with renal involvement caused by various sarcoidosis-associated pathophysiological conditions. *Intern Med* 2019; 58: 679-84.
45. Mahfoudhi M, Mamlouk H, Turki S, Kheder A. Systemic sarcoidosis complicated of acute renal failure: about 12 cases. *Pan Afr Med J* 2015; 22: 75.
46. Desai R, Kakumani K, Fong HK, et al. The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. *Ann Transl Med* 2018; 6: 330.
47. Yasuda M, Iwanaga Y, Kato T, et al. Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis. *Open Heart* 2016; 3: e000437.
48. Mahmoud AR, Dahy A, Dibas M, et al. Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis. *Heart Lung* 2020; 49: 512-7.
49. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. *Circ Cardiovasc Qual Outcomes* 2012; 5: 85-93.
50. Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous coronary intervention. In: StatPearls. StatPearls Publishing; 2023. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK556123/> Accessed December 17, 2023.
51. Rapoport EA, Chidharla A, Mortoti SS. A case of cardiac sarcoidosis with concurrent myocardial ischemia. *HeartRhythm Case Rep* 2021; 7: 479-83.
52. Rapoport EA, Chidharla A, Mortoti SS. A case of cardiac sarcoidosis with concurrent myocardial ischemia. *HeartRhythm Case Rep* 2021; 7: 479-83.
53. Rajkumar T, Lea-Henry T, Chacko B. Acute kidney injury as the presenting manifestation of sarcoidosis: a case series and review of literature. *Nephrology* 2018; 23: 597-600.
54. Wang C, Liu H, Zhang T, et al. Acute kidney injury as a rare manifestation of pediatric sarcoidosis: a case report and systematic literature review. *Clin Chim Acta* 2019; 489: 68-74.
55. Kikuchi H, Mori T, Rai T, Uchida S. Acute kidney injury caused by sarcoid granulomatous interstitial nephritis without extrarenal manifestations. *CEN Case Rep* 2015; 4: 212-7.
56. Goyal A, Daneshpajouhnejad P, Hashmi MF, et al. Acute Kidney Injury. [Updated 2023 Feb 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441896/>
57. Ibrik O, Samon R, Roda A, et al. Sarcoidosis: diagnosis from the renal function and hypercalcaemia study. *Nefrologia* 2011; 31: 321-7.
58. Manjunath V, Moeckel G, Dahl NK. Acute kidney injury in a patient with sarcoidosis: hypercalciuria and hypercalcemia leading to calcium phosphate deposition. *Clin Nephrol* 2013; 80: 151-5.